New algorithm aims to prevent organ rejection in young kidney patients
NCT ID NCT07549230
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will develop a computer tool to help doctors give the right dose of tacrolimus to children who have received a kidney transplant. The goal is to keep tacrolimus levels in a safe and effective range, reducing the risk of the body rejecting the new kidney. Researchers will use data from 130 children to build and test the dosing algorithm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tacrolimus
What this could lead to
If successful, this could provide a more accurate way to dose tacrolimus in children after kidney transplant, potentially lowering the chance of organ rejection.
What could go wrong
This is an early-stage study that has not yet started recruiting. The algorithm may not perform better than current methods, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.